



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Michael O. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Robert C. Milloring
Donald J. Featherstone
Lawrence B. Bugaisky
Michael V. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Albert L. Ferro* Donald R. Banowit Peter A. Jackman Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono

Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Prengaman Jane Shershenovich* George S. Bardmesser Daniel A. Klein* Daniel A. Klein*
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
LuAnne M. DeSantis
John J. Figueroa
Ann E. Summerfield Timothy A. Doyle

Gaby L. Longsworth* Nicole D. Dretar* Ted J. Ebersole Jyoti C. Iyer* Laura A. Vogel

Registered Patent Agents -Karen R. Markowicz Nancy J. Leith Helene C. Carlson Matthew J. Dowd Aaron L. Schwartz Katrina Y. Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford

Robert H. DeSelm Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse

<u>Of Counsel</u> Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

August 5, 2004

WRITER'S DIRECT NUMBER: (202) 772-8834 INTERNET ADDRESS: BHAANES@SKGF.COM

Art Unit 1639

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/052,942; Filed: January 23, 2002

Methods of Producing or Identifying Intrabodies in Eukaryotic Cells

Inventors:

ZAUDERER et al.

Our Ref:

1821.0090004/EKS/EJH/T-M

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Fourth Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
- 2. One (1) page of Form PTO-1449 citing two (2) documents:
- A copy of each of the two (2) cited documents (AR24 and AS24); and 3.
- 4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox P.L.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents August 5, 2004 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNA, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Elizabeth J. Haanes, Ph.D.

Aftorney for Applicants Registration No. 42,613

EJH/T-M/nef Enclosures

296254_1.DOC

NIE O 6 TOTAL ED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ZAUDERER et al.

Appl. No.: 10/052,942

Filed: January 23, 2002

For: Methods of Producing or Identifying Intrabodies in

Eukaryotic Cells

Confirmation No.: 1028

Art Unit: 1639

Examiner: Ponnaluri, P.

Atty. Docket: 1821.0090004/EKS/EJH/T-M

Fourth Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Supplemental Information Disclosure Statement filed on September 22, 2003, in connection with the above-captioned application. A copy of each document is provided.

The Examiner's attention is directed to the following application:

U.S. Application No. 10/465,808, filed June 20, 2003, now pending (Document No. AS24);

which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to this application, now or upon issuance of the present application as a patent. The Examiner is

respectfully requested to consider the cited application and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSZER, GOLDSTEIN & FOX P.L.L.C.

Elizabeth J. Haanes, Ph.D. Attorney for Applicants Registration No. 42,613

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

295325_1.DOC

As Filed On aug. 6, 2004

				CIPE					
\(\o\), \(\o\)					Page 1 of 1 ATTY_DOCKET NO APPLICATION NO.				
			(Anne o	ATTY. DOCKET NO. 1821.0090004/EJH/T-M		APPLICATION NO. 10/052,942		
		FORM I	PTO-1449 \	MIR 0 8 5004	FIRST NAMED INVENTOR				
FOURTH SU	IPPLEME	NTAL	INFORMATIO	ALDISCLOSURE	Zauderer, M., et al. FILING DATE ART UNIT				
STATEMENT					January 23, 2002 1639				
EXAMINER DOCUMENT									
INITIAL			MBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AA1								
	AB1								
	AC1		· ·						
	AD1								
	AE1								
	AF1								
	AG1								
	AH1								
	AI1								
	AJ1								
	AK								
-				EOPEIGN I	PATENT DOCUMENTS				
EXAMINER		DOC	CUMENT	IENT					
INITIAL		NUMBER		DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes	
	AL							No	
	АМ							Yes	
	AIVI	+		-				No Yes	
	AN					-		No Yes	
	AO							No	
	AP							Yes No	
	17		OTHER (I	ncluding Autho	or, Title, Date, Pertinent	Pages, e	tc.)	110	
	AR	<u>24</u>	Boder, E.T., et al., "Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity," <i>Proc. Natl. Acad. Sci. USA</i> 97:10701-10705, National Academy of Sciences. (September 2000)						
	AS	<u>24</u>	Copy of co-pending U.S. application No. 10/465,808, inventors Zauderer, M. et al., filed June 20, 2003 (NOT PUBLISHED)						
	AT								
EXAMINER						DA	DATE CONSIDERED		
EXAMINER: In	itial if refer	ence co	onsidered, whet	her or not citation is	in conformance with MPEP 60	9. Draw line	through citation if no	t in conformance	
and not conside	ered. Inclu	de copy	of this form wit	th next communicati	on to Applicant,				

295290_1.DOC